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Abstract. 
In this cross-sectional seroepidemiological study we sought to examine the evidence for circulation of Rift Valley 
fever virus (RVFV) among herders in Madagascar and Kenya. From July 2010 to June 2012, we enrolled 459 
herders and 98 controls (without ruminant exposures) and studied their sera (immunoglobulin G [IgG] and IgM 
through enzyme-linked immunosorbent assay [ELISA] and plaque reduction neutralization test [PRNT] assays) for 
evidence of previous RVFV infection. Overall, 59 (12.9%) of 459 herders and seven (7.1%) of the 98 controls were 
positive by the IgG ELISA assay. Of the 59 ELISA-positive herders, 23 (38.9%) were confirmed by the PRNT assay 
(21 from eastern Kenya). Two of the 21 PRNT-positive study subjects also had elevated IgM antibodies against 
RVFV suggesting recent infection. Multivariate modeling in this study revealed that being seminomadic (odds ratio 
[OR] = 6.4, 95% confidence interval [CI] = 2.1–15.4) was most strongly associated with antibodies against RVFV. 
Although we cannot know when these infections occurred, it seems likely that some interepidemic RVFV infections 
are occurring among herders. As there are disincentives regarding reporting RVFV outbreaks in livestock or 
wildlife, it may be prudent to conduct periodic, limited, active seroepidemiological surveillance for RVFV infections 
in herders, especially in eastern Kenya. 
INTRODUCTION 
Since its first discovery in 1931,
1,2
 Rift Valley fever virus (RVFV) has been detected in 
various sub-Saharan countries, as well as Egypt, Saudi Arabia, and Yemen, causing numerous 
outbreaks among both animals and humans.
3–6
 Kenya’s most recent Rift Valley Fever (RVF) 
outbreak of 2006–2007 spread to multiple provinces and districts and resulted in nearly 400 
cases of severe illness with at least 118 human deaths.
5,7
 Epidemiological data collected from 
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some of the patients demonstrated that two-thirds were exposed to a recently ill animal before 
infection.
8
 In addition, data suggested that other risk factors, including drinking raw milk, 
owning an ill animal, working as a herdsman, and slaughtering an animal, were also associated 
with RVFV infection.
5,8
 
From January to May 2008 and from November 2008 to March 2009, a RVFV strain, similar 
to that identified in the 2006–2007 outbreaks in Kenya, was identified as the causative agent in 
human and animal outbreaks across Madagascar, which resulted in a total of 26 human deaths.
9
 
However, this was not the first epizootic to occur in Madagascar, as outbreaks were also reported 
in the east coast in 1990 and 1991, which resulted in increased abortion rates among pregnant 
cattle by 17% and 15%, respectively.
10,11
 
Following these outbreaks, it has been strongly suggested that enhanced surveillance should 
be implemented to more effectively predict and respond to future outbreaks.
9
 Though positive 
gains have been made to monitor RVFV in these countries, little is known regarding the 
maintenance of the virus during interepidemic periods.
12–17
 In an effort to better understand the 
ecology of human RVFV infections, we conducted this cross-sectional, seroepidemiological 
study of persons with intense exposure to ruminants living in eastern Kenya, western Kenya, and 
Madagascar. 
METHODS 
Study settings and design. 
This study was approved by Western Institutional Review Board and institutional review 
boards from collaborating institutions at each of the study sites (eastern Kenya—KEMRI Non-
SSC no. 291, western Kenya—KEMRI SC1701, and Madagascar). Study personnel from each 
study site used informed consent to enroll participants  18 years of age who had a history of 
contact with ruminants. In Madagascar, participants were enrolled from the districts of 
Antsirabe, Antsohihy, Ihosy, Miandrivazo, Nosy Be, Toliara, Toliara II, and Tsiroanomandidy 
during the period January–March 2012 (Figure 1A). In eastern Kenya, participants were enrolled 
from the villages of Gababa, Haji Mohamed, Hathama Chari, and Masalani in the North Eastern 
Province (Figure 1B) during February 6–12, 2012. In western Kenya, participants were enrolled 
from the Western Province (Figure 1B) during July 2010 to June 2012. 
Ruminant exposure was defined as having an average of one or more cumulative hours per 
week exposure to camels, cattle, goats, or sheep, either by contact through touching and/or 
coming within 1 m of such animals during the 12 months before enrollment. Participants 
enrolled as controls resided in the same areas, denied having such contact, and when possible, 
were loosely age, group, and gender matched to exposed participants based on an expected final 
distribution of exposed study participants. Exclusion criteria for both groups included individuals 
less than 18 years of age, having any reported immunosuppression, or having been identified as 
medically likely to have greater susceptibility to various infectious agents. 
Sample collection. 
On enrollment, participants completed an enrollment questionnaire with questions about 
demographics, animal and environmental exposures, and relevant medical information. 
Participants then permitted a serum sample collection, which was preserved at 80°C. Aliquots 
of serum were later shipped on dry ice to the University of Florida Emerging Pathogens Institute 
where they were first screened for human anti-RVF immunoglobulin G (IgG) antibodies with an 
enzyme-linked immunosorbent assay (ELISA). ELISA-positive samples were then tested with a 
plaque reduction neutralization test (PRNT) for validation. Finally, PRNT-positive samples were 
tested for human anti-RVF IgM antibodies with ELISA to delineate acute infections. 
IgG enzyme-linked immunosorbent assay. 
Sera received from Madagascar and Kenya were first heat inactivated for 30 minutes at 56°C 
and then screened for IgG antibodies using a commercial RVFV human IgG ELISA kit obtained 
from Biological Diagnostic Supplies Limited (Scotland, United Kingdom) according to the 
manufacturer’s instructions. In brief, plates were coated with a recombinant nucleocapsid RVFV 
antigen diluted 1:1,000 in sodium bicarbonate buffer (pH = 9.6), covered with plate seals, and 
incubated at 4°C overnight. Unbound antigen was removed by washing three times for 15 
seconds each using phosphate-buffered saline with 0.05% Tween 20 (PBS-T). Plates were then 
blocked with 10% (w/v) skimmed milk powder (SM) in PBS at 37°C for 1 hour. Plates were 
washed with PBS-T, test sera added in duplicate at a dilution of 1:400 in PBS + 2% (w/v) SM, 
and incubated for 1 hour at 37°C. Plates were washed once more, and horseradish peroxidase 
(HRP)–conjugated antihuman IgG antibody, diluted 1:25,000 in PBS + 2% (w/v) SM, was added 
to each well and incubated for 1 hour at 37°C. After a final wash, chromogenic detection of HRP 
was performed by the addition of 0.1 mL of the peroxidase substrate 3,3,5,5-
tetramethylbenzidine (TMB) (KPL, Inc., Gaithersburg, MD), at room temperature for 10 minutes 
and stopped by the addition of 0.1 mL 1 N sulfuric acid.
18
 Absorbance of each well at 450 nm 
(A450) was measured by a PowerWave HT microplate spectrophotometer (Biotek, Winooski, 
VT). Negative and positive control sera were included for each plate. Sera samples were 
considered positive if their OD calculation was  0.29 (net OD serum/net mean OD positive 
control). 
Plaque reduction neutralization test. 
All samples testing positive by the ELISA kit were further studied using PRNT adapted from 
methods previously described.
19,20
 RVFV MP-12 vaccine strain, propagated in Vero-CCL81 
cells, was used in the PRNT assay. Sera were tested in duplicate using six 4-fold dilutions 
starting with 1:10 and ending at 1:10,240. A back titration of the diluted stock MP-12 virus was 
performed each time assays were run to ascertain the titer of virus stock used (typically, 30–60 
plaque forming units/mL). A neutralization cutoff of 80% reduction, as determined by a 
corresponding back titration plate, was used to determine sera titration. 
IgM enzyme-linked immunosorbent assay. 
To ascertain whether an individual had evidence of an acute infection, an indirect capture 
ELISA, adapted in-house following the principles of Paweska and others,
21
 was used. Because of 
having a limited amount of test serum and reagents, IgM testing was performed only for 
individuals who tested positive with the PRNT assay. First, 96-well microtiter plates were coated 
with a goat antihuman IgM antibody (catalog no. 01-10-03; KPL, Inc.) at a dilution of 1:2,000 in 
sodium bicarbonate buffer (pH = 9.6), covered with plate seals and incubated at 4°C overnight. 
Unbound antibody was washed from the well with PBS-T, and plates were then blocked with 
PBS with 5% (w/v) SM at room temperature for 2 hours. Test sera, diluted 1:100 in PBS-T plus 
5% (w/v) SM, were added to coated plates and allowed to incubate for 1 hour at 37°C. Gamma-
irradiated RVFV antigen, obtained from BEI Resources (NIAID, NIH, RVFV, ZH501, Gamma-
irradiated, NR-37380), was diluted 1:1,000 in PBS-T with 5% (w/v) SM, added to the plates, and 
allowed to incubate for 1 hour at 37°C. Rabbit anti-RVFV polyclonal antibody, obtained from 
Integrated Biotherapeutics Inc. (catalog no. 04-0001; Gaithersburg, MD), was diluted 1:1,000 in 
PBS-T with 5% SM, added to the plates, and allowed to incubate for 1 hour at 37°C. Extra serum 
adsorbed HRP-conjugated goat anti-rabbit IgG antibody (catalog no. 074-15-061, KPL, Inc.) was 
diluted 1:2,000, added to each well, and incubated for 1 hour at 37°C. All wells were washed 
five times after each incubation step using PBS-T. Each plate contained a “no antigen” negative 
control well to adjust for background absorbance. Chromogenic detection of HRP and plate 
reading was performed as described above. An IgM-positive control sample was not available for 
this assay. Instead, serum samples collected from six individuals with no possible RVFV 
exposure were collected and included in the assay run. IgM positivity was defined as any sample 
with an average A450 OD greater than three times the standard deviation plus the average A450 
OD of the six negative control sera. 
Statistical analysis. 
Bivariate 2 tests of independence or Fisher’s exact test were used to examine the association 
of demographic variables where PRNT serological outcomes were available. ELISA IgG 
positivity was used as the outcome variable when PRNT serological outcomes were not 
available. Variables determined by bivariate analyses to be statistically associated with RVFV 
seropositivity (P < 0.25) were then entered into a multivariable unconditional logistic regression 
model. Backward elimination was performed and covariates with P < 0.05 were retained in the 
model. Individual predictors retained in the final logistic models were tested for collinearity 
using bivariate 2 tests. Finally, Hosmer–Lemeshow 2 statistics for goodness of fit were 
performed. All demographic statistics, bivariate testing, and logistic modeling were conducted 
using SAS version 9.3 (SAS Institute, Cary, NC). 
RESULTS 
Study population. 
In Madagascar, participants were enrolled from the north, central, and south regions of the 
country, representing each of the unique climatic regions (Figure 1). Madagascar is an island 
nation with a population of nearly 23 million, located approximately 250 miles off the eastern 
coast of the African continent, south of the Equator. It is bordered to the west by the 
Mozambique Channel and to the east by the Indian Ocean. Participants were also enrolled from 
areas in the eastern and western regions of Kenya, a country of over 44 million population. In 
eastern Kenya, individuals were enrolled in Garissa County, which is bordered by Somalia to the 
east and also where RVFV cases have been previously reported. The human populations in this 
area are seminomadic pastoralists, which depend on livestock herds for survival. In western 
Kenya, participants were enrolled in the formerly named Western Province, which is bordered by 
Lake Victoria to the south and Uganda to the west. This region of Kenya has a mixed crop–
livestock farming system and a high human population density, with a heavy endemic and 
epidemic disease burden on both humans and animals. Western Kenya contains a range of 
ecological settings from the Lake Victoria system in the south to a semi-mountain system on the 
lower slopes of Mount Elgon in the north. 
We enrolled 127 participants (93 exposed and 34 controls) from Madagascar, 230 
participants (all exposed) from eastern Kenya, and 200 participants (136 exposed and 64 
controls) from western Kenya (Table 1). 
ELISA and plaque reduction neutralization test. 
Of the 127 samples collected from Madagascar and tested by the ELISA assay, eight (6.3%) 
screened positive for IgG antibodies, of which two were confirmed positive by the PRNT assay 
at a sera dilution of 1:160 and 1:640. Between the two confirmed IgG PRNT-positive samples, 
both were from individuals with exposure to ruminants (two of 93 exposed = 2.15% RVFV 
positive) (Table 2). One of the two IgG PRNT-positive samples, which had a titer of 1:640, also 
tested positive by ELISA for IgM antibodies. This sample was collected from a man of 58 years, 
with daily reported exposure to cattle, who lived in Tsiroanomandidy and had no travel history 
outside Madagascar. This individual also reported monthly handling of raw meat and butchering, 
frequently sleeping outside close to his cattle, and reported regular exposure to mosquito bites. 
Despite being IgM positive, there were no reported symptoms of fever or being sick during the 
last 12 months. Of the 230 samples collected from eastern Kenya and tested by the ELISA assay, 
36 (15.7%) screened positive for IgG antibodies. Of these 36 samples, 21 (58.3%) were 
confirmed positive by PRNT assay at a sera dilution  1:40. The titer range for the exposed 
confirmed positives was 1:160 to 1:2,560, and the age ranged from 18 to 65 years with a mean of 
37.6 years (Table 2 and Figure 2). Of the 200 samples collected from western Kenya and tested 
by the ELISA assay, 15 screened positive for IgG antibodies, though, none of these samples were 
confirmed positive by PRNT assay. 
Bivariate and multivariate analysis. 
As a positive PRNT assay is less prone to cross-reactive biases, PRNT positivity was the 
outcome of choice for examining risk factor associations. Data from eastern Kenya were robust 
enough for examining PRNT as an outcome. However, as both Madagascar and western Kenyan 
sample populations yielded few PRNT positives, instead of PRNT, we examined ELISA IgG 
seropositivity as a surrogate for PRNT positivity. Bivariate and multivariate modeling results are 
recorded in Tables 3 and 4. Important bivariate risk factors for RVFV seropositivity included 
being seminomadic, drinking water from a public well or borehole, sleeping under a mosquito 
net, being bitten by a mosquito in the past 12 months, and wearing protective clothing when 
working with animals in the past 12 months (Table 3). Only the model for eastern Kenya yielded 
statistically significant risk factor associations with RVFV seropositivity: being seminomadic 
(odds ratio [OR] = 6.4, 95% confidence interval [CI] = 2.1–15.36) and sleeping under a mosquito 
net (OR = 3.2, 95% CI = 1.1–9.6). No collinearity problems were detected between any of the 
variables. Hosmer–Lemeshow 2 statistics for goodness of fit indicated that predictors 
sufficiently described the data. 
DISCUSSION 
RVFV infections are considered as a major threat to the agricultural economies of many of 
the world’s nations where competent mosquito vectors are endemic. Although previously 
contained in Africa and Middle East, experts have argued that considering modern transportation 
and trade routes, RVFV poses a large threat to the European Union and the United States.
22,23
 
Realizing this threat, the U.S. government is investing considerable funding in understanding the 
ecology of RVFV and in developing better diagnostics and vaccines.
24
 As part of this effort, we 
conducted this cross-sectional seroepidemiological study to assess human evidence of RVFV 
infection. 
In general, our seroepidemiological study did not yield evidence for many unrecognized 
human RVFV infections in the three geographical areas we examined. However, because some 
of our seropositive study subjects were relatively young, our data suggest that indeed some 
human RVFV infections may be occurring during interepidemic periods. This would support the 
notion that passive surveillance for RVFV is not highly effective in detecting new epidemic 
threats. Our findings are also remarkable in that seropositivity was confirmed only among those 
with exposures to ruminants, and the risk factors of being seminomadic are consistent with our 
understanding of the ecology of RVFV infections. 
The use of bed netting to reduce exposure to mosquitoes also had a positive association with 
RVFV seropositivity, which may seem unexpected; however, it may be explained by 
confounders that were not assessed by our survey. Possible confounders include differences in 
vector species and behavior, particularly as it relates to host seeking and feeding. For example, 
the protective effect of bed netting would be markedly reduced if RVFV mosquito vectors in a 
given area were predominantly daytime biters or with exophagic behavior. In addition, it is 
possible that individuals who reported using bed netting were also more likely to be in areas with 
higher densities of mosquitoes, resulting in an overall increased risk of exposure. This finding 
underscores the need to better understand vector ecology as it applies to RVFV transmission in 
interepidemic areas, however, it is to be noted that bed nets remain an effective method for the 
prevention of vector-borne diseases of public health importance such as malaria. 
Our study had several limitations. Its cross-sectional nature makes it difficult for us to 
understand when the RVFV infections may have occurred among study subjects. Also, while we 
can infer some exposure information by the age of the seropositive subject, the precision of this 
association is poor. Prospective studies are a much better approach to estimating risk of human 
infection over time. The study is also limited in that we used slightly different approaches in 
sampling (sample population from eastern Kenya were all exposed) and in questioning the study 
subjects (instruments differed slightly between sites). 
Considering our three sampling areas in this work and another similar study we conducted in 
Saudi Arabia,
25
 our findings suggest that we are not missing large outbreaks of RVFV infections 
in the current surveillance and reporting systems. However, it does seem likely that small 
outbreaks, which affect both animals and man, may be missed or unreported. While one might 
argue that animals are the most sensitive sentinels for RVFV outbreaks, there are considerable 
disincentives for reporting RVFV outbreaks. Hence, conducting limited active surveillance for 
RVFV in man may be an important supplement to the surveillance that is conducted among 
domestic animals and wildlife. In particular, eastern Kenya would seem a good site to conduct 
such active surveillance for RVFV in herders. For instance, periodically screening subsets of 
herders for serological evidence of RVFV infection at various primary care clinics and hospitals 
in this region would seem a prudent and likely inexpensive additional early warning measure. 
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FIGURE 1. Maps of locations where study subjects were enrolled. (A) Location of study subjects in Madagascar. (B) 
Provinces in Kenya where study subjects were enrolled: 1, Western Province (N = 200 participants); 2, Garissa 
County (formerly North Eastern Province) (N = 230 participants). 
 
 
FIGURE 2. Distribution of plaque reduction neutralization test (PRNT) positives (%) by age group from eastern 
Kenya. 
 
 
 
 
 
 
TABLE 1 
Demographic characteristics of the study participants enrolled in 2012, Madagascar and Kenya 
Demographic characteristics 
Madagascar Eastern Kenya Western Kenya 
Exposed* Nonexposed Exposed* Exposed* Nonexposed 
n (%) n (%) n (%) n (%) n (%) 
Total 93 (100) 34 (100) 230 (100) 136 (100) 64 (100) 
Gender 
 Male 82 (88) 11 (32) 76 (33) 61 (45) 25 (39) 
 Female 10 (11) 24 (71) 154 (67) 75 (55) 39 (61) 
Age group (years) 
 18–28 32 (34) 10 (29) 58 (25) 54 (40) 21 (33) 
 29–44 37 (40) 11 (32) 100 (44) 39 (29) 22 (34) 
 45–60 18 (19) 10 (29) 55 (24) 25 (18) 9 (14) 
 > 60 5 (5) 4 (12) 17 (7) 18 (13) 12 (19) 
Madagascar (districts) 
 Antsirabe 8 (9) 2 (6) – – – 
 Antsohihy 5 (5) 3 (9) – – – 
 Ihosy 44 (47) 16 (47) – – – 
 Miandrivazo 10 (11) 9 (26) – – – 
 Nosy Be 4 (4) 1 (3) – – – 
 Toliara 0 (0) 1 (3) – – – 
 Toliara II 12 (13) 1 (3) – – – 
 Tsiroanomandidy 9 (10) 2 (6) – – – 
Eastern Kenya (village) 
 Gababa – – 34 (15) – – 
 Haji Mohamed – – 150 (65) – – 
 Hathama Chari – – 17 (7) – – 
 Masalani – – 29 (13) – – 
Western Kenya (tribe) 
 Japadhola – – – 0 (0) 1 (1.5) 
 Kikuyu – – – 0 (0) 1 (1.5) 
 Luhya – – – 63 (9) 22 (34) 
 Luo – – – 29 (5) 17 (27) 
 Samia – – – 21 (48) 6 (9) 
 Teso – – – 23 (11) 17 (27) 
* Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 
12 months before enrollment. 
 
 
 
 
 
 
TABLE 2 
Demographic and exposure characteristics of the 23 study subjects PRNT-positive for antibodies against RVFV 
No. Site enrolled Ruminant exposed* Gender Age group PRNT titer IgM positive 
1 Madagascar Yes Male 45–60 1:640 Yes 
2 Madagascar No Male 45–60 1:160 No 
3 Eastern Kenya Yes Male 45–60 1:640 No 
4 Eastern Kenya Yes Female 29–44 1:160 No 
5 Eastern Kenya Yes Female 29–44 1:640 No 
6 Eastern Kenya Yes Female 45–60 1:640 No 
7 Eastern Kenya Yes Female 29–44 1:160 No 
8 Eastern Kenya Yes Female 29–44 1:640 No 
9 Eastern Kenya Yes Female 29–44 1:160 No 
10 Eastern Kenya Yes Male 29–44 1:160 No 
11 Eastern Kenya Yes Female 29–44 1:640 No 
12 Eastern Kenya Yes Female > 60 1:160 No 
13 Eastern Kenya Yes Female 29–44 1:2,560 No 
14 Eastern Kenya Yes Female 45–60 1:640 No 
15 Eastern Kenya Yes Female 45–60 1:160 No 
16 Eastern Kenya Yes Male 18–28 1:640 No 
17 Eastern Kenya Yes Female 18–28 1:2,560 No 
18 Eastern Kenya Yes Male 18–28 1:160 No 
19 Eastern Kenya Yes Female 18–28 1:160 No 
20 Eastern Kenya Yes Female 29–44 1:640 No 
21 Eastern Kenya Yes Female 18–28 1:160 No 
22 Eastern Kenya Yes Male 29–44 1:640 No 
23 Eastern Kenya Yes Male 45–60 1:160 No 
IgM = immunoglobulin M; PRNT = plaque reduction neutralization test; RVFV = Rift Valley fever virus. 
* Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 
12 months before enrollment. 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3 
Unadjusted ORs for risk factors associated with evidence of previous RVFV infection based on ELISA IgG 
seropositivity (Madagascar and western Kenya) 
Risk factor 
Madagascar Western Kenya 
Total 
N 
No. (%) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Total 
N 
No. (%) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Ruminant exposure* 
 Yes 93 6 (6.5) 1.1 (0.21, 5.8) – 136 10 (7.4) 0.94 (0.31, 2.9) 
– 
 No 34 2 (5.9) Ref. 64 5 (7.8) Ref. 
Age (years) 
 18–28 42 3 (7.1) 1.2 (0.28, 5.4) 
– 
75 6 (8.0) 1.1 (0.38, 3.3) 
– 
 29–44 48 0 (0) – 61 3 (4.9) 0.55 (0.15, 2.0) 
 45–60 28 4 (14.3) 4.0 (0.92, 17.0) 34 2 (5.9) 0.74 (0.16, 3.4) 
 > 60 9 1 (11.1) 2.0 (0.22, 18.2) 30 4 (13.3) 2.2 (0.66, 7.5) 
Gender 
 Female 34 2 (5.9) 0.91 (0.17, 4.7) 
– 
114 7 (6.1) 0.64 (0.22, 1.8) 
– 
 Male 93 6 (6.5) Ref. 86 8 (9.3) Ref. 
Seminomadic 
 Yes 1 0 (0) 
– – N/A N/A N/A N/A 
 No 125 8 (6.4) 
Drinking water from public well/borehole 
 Yes 58 3 (5.2) 0.70 (0.16, 3.05) 
– 
83 6 (7.2) 0.94 (0.32, 2.7) 
– 
 No 69 5 (7.2) Ref. 117 9 (7.7) Ref. 
Sleep under a mosquito net 
 Yes 96 5 (5.2) 0.51 (0.12, 2.28) 
– N/A N/A N/A N/A 
 No 31 3 (9.7) Ref. 
Bitten by a mosquito in past 12 months 
 Yes 123 7 (5.7) 0.51 (0.12, 2.3) 
– N/A N/A N/A N/A 
 No 4 1 (25.0) Ref. 
Wear protective clothing when working with animals in past 12 months 
 Yes 3 0 (0) 
– – N/A N/A N/A N/A 
 No 116 8 (6.9) 
Cared for birthing animal in past 12 months 
 Yes 2 0 (0) 
– – 
19 0 (0) 
– – 
 No 124 8 (6.9) 181 15 (8.3) 
Butchered animal in past 12 months 
 Yes 67 5 (7.5) 1.5 (0.35, 6.7) 
– 
34 3 (8.8) 1.2 (0.33, 4.7) 
– 
 No 60 3 (5.0) Ref. 166 12 (7.2) Ref. 
Reported fever in past 12 months 
 Yes 46 4 (8.7) 1.8 (0.44, 7.7) 
– 
120 8 (6.7) 0.74 (0.26, 2.1) 
– 
 No 81 4 (4.9) Ref. 80 7 (8.8) Ref. 
CI = confidence interval; ELISA = enzyme-linked immunosorbent assay; IgG = immunoglobulin G; N/A = data 
were not available for this covariate; OR = odds ratio; RVFV = Rift Valley fever virus. 
* Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 
12 months before enrollment. 
 
 
TABLE 4 
Unadjusted and adjusted ORs for risk factors associated with evidence of previous RVFV infection by elevated 
PRNT assay (eastern Kenya) 
Risk factor 
Eastern Kenya 
Total N No. (%) Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Ruminant exposure* 
 Yes 0 0 (0) 
– – 
 No 230 21 (9.1) 
Age (years) 
 18–28 53 4 (7.5) 0.95 (0.40, 2.2) 
– 
 29–44 103 10 (9.7) 0.75 (0.36, 1.6) 
 45–60 55 5 (9.1) 1.8 (0.81, 3.8) 0.32 (0.04, 2.5) 
 > 60 17 1 (5.9) – 
Gender 
 Female 154 15 (9.7) 1.3 (0.5, 3.4) 
– 
 Male 76 6 (7.9) Ref. 
Seminomadic 
 Yes 77 15 (19.5) 5.9 (2.2, 16.0) 6.4 (2.1, 15.4) 
 No 153 6 (3.9) Ref. Ref. 
Drinking water from public well/borehole 
 Yes 65 11 (16.9) 3.2 (1.3, 7.9) 
– 
 No 165 10 (6.0) Ref. 
Sleep under a mosquito net 
 Yes 27 6 (22.2) 3.6 (1.3, 10.2) 3.2 (1.1, 9.6) 
 No 203 15 (7.4) Ref. Ref. 
Bitten by a mosquito in past 12 months 
 Yes 116 15 (12.9) 2.7 (1.0, 7.2) 
–  No 114 6 (5.3) Ref. 
Wear protective clothing when working with animals in past 12 months 
 Yes 17 4 (23.5) 3.5 (1.0, 11.9) 
– 
 No 210 17 (8.1) Ref. 
Cared for birthing animal in past 12 months 
 Yes 224 20 (8.9) 0.39 (0.04, 3.7) 
– 
 No 5 1 (20.0) Ref. 
Butchered animal in past 12 months 
 Yes 212 20 (9.4) 1.6 (0.2, 12.5) 
– 
 No 16 1 (6.3) Ref. 
Reported fever in past 12 months 
 Yes 186 14 (7.5) 0.43 (0.16, 1.1) 
– 
 No 44 7 (15.9) Ref. 
CI = confidence interval; PRNT = plaque reduction neutralization test; OR = odds ratio; RVFV = Rift Valley fever 
virus. 
* Exposure was defined as close contact through touching and/or coming within 1 m of a ruminant animal during the 
12 months before enrollment. 
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